Phase 2 interim data show rezatapopt yields meaningful responses in heavily pretreated ovarian cancer patients with TP53 Y220C mutation
Alison Schram, MD presented interim results from the PYNNACLE Phase 2 trial of rezatapopt, a selective p53 reactivator, in patients whose tumors carry the TP53 Y220C mutation.
The analysis focused on a cohort with advanced or metastatic ovarian cancer that had been heavily pretreated. Single‑agent rezatapopt produced clinically meaningful tumor responses, indicating activity against this hard‑to‑treat genetic subtype.
Safety was reported as manageable, with no new safety signals emerging in this interim assessment. The data suggest the drug may offer a new therapeutic option for patients with limited alternatives.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer”
read at onclive ↗
comments(0)
5-min edit window · permanent after that